Market Cap 302.20M
Revenue (ttm) 36.33M
Net Income (ttm) -85.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -234.38%
Debt to Equity Ratio -2.40
Volume 10,898,600
Avg Vol 1,751,720
Day's Range N/A - N/A
Shares Out 53.30M
Stochastic %K 63%
Beta 0.31
Analysts Sell
Price Target $11.84

Company Profile

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 517 0730
Address:
25 Mall Road, Suite 203, Burlington, United States
BDE_Worldwide
BDE_Worldwide Jul. 28 at 7:48 PM
$SCPH anyone tracking SCPH product sales at $MNKD? Are they going to have to pay us the additional $0.25/share? SCPH product sales need to exceed $120MM in 2026 to trigger the additional payment.
1 · Reply
BDE_Worldwide
BDE_Worldwide Jul. 28 at 6:27 AM
$SCPH $0.75/share coming our way! https://mannkindcorp.com/furoscixnews/
0 · Reply
JFais
JFais Jul. 24 at 9:21 PM
Another takeaway from $SCPH & a few others in the past year for that matter $DAWN $APLS $SLNO Forced selling taking place before buyout on the cheap (need an artificially high premium) $XBI
0 · Reply
JFais
JFais Jul. 24 at 9:16 PM
$MNKD (NP) Furoscix autoinjector approved (snagged from $SCPH on cheap buyout, final trade chart from that one below) Set price alerts at $3.50 in case it pulls back (should see nice multi-year revenue ramp & perhaps additional tech partnerships, not only with $UTHR) Nintedanib in IPF not be overlooked either IMO
0 · Reply
MITornado
MITornado Jul. 24 at 5:04 PM
$SCPH gotta love AI
0 · Reply
MITornado
MITornado Jul. 24 at 4:55 PM
$SCPH what was the additional payout for approval of the auto injector and when will it be paid out?
1 · Reply
BeefStewart
BeefStewart Jul. 21 at 12:37 AM
$RCEL I sincerely believe this is a takeover target, similar to how $SCPH was a takeover target last year. They are burning cash, but also starting to show meaningful signs of growth, in my opinion. I can see this going to $10+ if earnings are excellent, and I believe a $600M valuation is not crazy if all goes amazingly well. Having said that, I anticipate that they will raise capital shortly after Q2 ER next month, so I understand that can influence the valuation if dilution is involved, which seems like a reasonable (and arguably likely) possibility based on management's language after the Q1 ER. If they don't raise cash shortly after, perhaps they are open to a sale of the company. I would love to see $20 per share by end of this year. This is purely speculation on my part, though. Always do your own research and due diligence. Please fact check my post in case I got anything wrong.
0 · Reply
clan
clan Jul. 17 at 10:00 PM
$MNKD Mannkind acquiring SCPharma $SCPH and folding it in as a division of Mannkind, and operating as is, allows Mannkind to use SCPharma's ~$200,000,000 in capital loss carryforewards against coming Earnings/Profits as offsets to negate what would have been tax burdens. Huge! Benefit! Huge!
0 · Reply
clan
clan Jul. 5 at 5:52 PM
$MNKD Mannkind with an advancing, productive, and prosperous pipeline... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $2 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $7 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug 👈👀😲🤑 -------- +$48/sh $SPY 👀 🇺🇲💪
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Jun. 23 at 10:43 PM
$SPCX $SCPH $SSPC these could have a lil rebound if INDICES behave tomm
0 · Reply
Latest News on SCPH
BDE_Worldwide
BDE_Worldwide Jul. 28 at 7:48 PM
$SCPH anyone tracking SCPH product sales at $MNKD? Are they going to have to pay us the additional $0.25/share? SCPH product sales need to exceed $120MM in 2026 to trigger the additional payment.
1 · Reply
BDE_Worldwide
BDE_Worldwide Jul. 28 at 6:27 AM
$SCPH $0.75/share coming our way! https://mannkindcorp.com/furoscixnews/
0 · Reply
JFais
JFais Jul. 24 at 9:21 PM
Another takeaway from $SCPH & a few others in the past year for that matter $DAWN $APLS $SLNO Forced selling taking place before buyout on the cheap (need an artificially high premium) $XBI
0 · Reply
JFais
JFais Jul. 24 at 9:16 PM
$MNKD (NP) Furoscix autoinjector approved (snagged from $SCPH on cheap buyout, final trade chart from that one below) Set price alerts at $3.50 in case it pulls back (should see nice multi-year revenue ramp & perhaps additional tech partnerships, not only with $UTHR) Nintedanib in IPF not be overlooked either IMO
0 · Reply
MITornado
MITornado Jul. 24 at 5:04 PM
$SCPH gotta love AI
0 · Reply
MITornado
MITornado Jul. 24 at 4:55 PM
$SCPH what was the additional payout for approval of the auto injector and when will it be paid out?
1 · Reply
BeefStewart
BeefStewart Jul. 21 at 12:37 AM
$RCEL I sincerely believe this is a takeover target, similar to how $SCPH was a takeover target last year. They are burning cash, but also starting to show meaningful signs of growth, in my opinion. I can see this going to $10+ if earnings are excellent, and I believe a $600M valuation is not crazy if all goes amazingly well. Having said that, I anticipate that they will raise capital shortly after Q2 ER next month, so I understand that can influence the valuation if dilution is involved, which seems like a reasonable (and arguably likely) possibility based on management's language after the Q1 ER. If they don't raise cash shortly after, perhaps they are open to a sale of the company. I would love to see $20 per share by end of this year. This is purely speculation on my part, though. Always do your own research and due diligence. Please fact check my post in case I got anything wrong.
0 · Reply
clan
clan Jul. 17 at 10:00 PM
$MNKD Mannkind acquiring SCPharma $SCPH and folding it in as a division of Mannkind, and operating as is, allows Mannkind to use SCPharma's ~$200,000,000 in capital loss carryforewards against coming Earnings/Profits as offsets to negate what would have been tax burdens. Huge! Benefit! Huge!
0 · Reply
clan
clan Jul. 5 at 5:52 PM
$MNKD Mannkind with an advancing, productive, and prosperous pipeline... APPROVALS {and eventual accretive} ADDS TO MNKD SHARE PRICE [B4 EOY 2028]: + $4 -- acquisition of scPharma [ $SCPH ] + $4 -- label change - Afrezza + $2 -- Afrezza in India + $6 -- pediatric Afrezza + $8 -- FDA approval of Furoscix auto injector + $2 -- gestational Afrezza + $6 -- Ralinepag DPI [MNKD-1501 $UTHR ] + $7 -- Nintedanib DPI [MNKD-201] + $3 -- Bumetanide DPI [MNKD-701] + $6 -- Tyvaso DPI bridge for IPF & PPF + $? -- Undisclosed drug 👈👀😲🤑 -------- +$48/sh $SPY 👀 🇺🇲💪
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Jun. 23 at 10:43 PM
$SPCX $SCPH $SSPC these could have a lil rebound if INDICES behave tomm
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Jun. 16 at 3:01 PM
$SPCX $SCPH + $SSPC <-2 NEW ETF'S TODAY
0 · Reply
clan
clan Jun. 3 at 5:46 PM
$MNKD APPROVED! APPROVED! APPROVED! Goin' for 4 in a row! Ready to Flow! $SPY $IBB $SCPH
1 · Reply
clan
clan Jun. 2 at 1:13 PM
$MNKD When you hear "Furoscix ReadyFlow autoinjector", think "gravy train"! 🤑💲💵💲🤑 $SCPH $IBB $BX 🐂
1 · Reply
BeefStewart
BeefStewart May. 19 at 2:48 PM
$RCEL this is behaving in a way that reminds me of $SCPH the arbitrary, low-volume selloffs... The low cash position, yet high margins and sequential growth. I believe this will be much higher by mid to late August. Perhaps it will be acquired the way SCPH was. $XBI $SPY
1 · Reply
BeefStewart
BeefStewart May. 15 at 8:24 PM
$RCEL Volume was great; but the lack of power was disappointing. I believe this is significantly undervalued, and I also believe there is a real chance that this gets acquired in or before August, similar to how ScPharmaceuticals $SCPH was last August. My reasoning is that it's a high-margin, growing business that has limited cash. A strategic buyer can swoop in asap and try to get this for 300 million or less in the near-term, or they can wait a little longer and maybe offer north of 500 million if sequential growth continues to build each quarter. Just speculation on my part; but this looks very solid.
0 · Reply
JFais
JFais May. 13 at 6:55 PM
Finished DD on new Playbook setup, now moving on to $MNKD on current pullback after $UTHR ralinepag DPI collab announced Still upset they acquired my $SCPH shares on the cheap (Furoscix autoinjector with July 26 PDUFA date, $500M+ opportunity)
0 · Reply
scottgrant2
scottgrant2 May. 11 at 2:29 AM
0 · Reply
BeefStewart
BeefStewart May. 10 at 11:54 PM
$RCEL @scottgrant2 Absolutely about disciplined spending and deeper penetration into existing burn centers, as well as expanding the range of products (in the medium term) that will be available so that Avita can offer more comprehensive treatments for wound care. I believe the company has moved past it's lowest point, and I wouldn't be completely shocked if it gets acquired at a potentially frustrating valuation (for longer-term shareholders), similar to how $MNKD acquired $SCPH
0 · Reply
BeefStewart
BeefStewart May. 10 at 11:53 PM
@scottgrant2 Absolutely about disciplined spending and deeper penetration into existing burn centers, as well as expanding the range of products (in the medium term) that will be available so that Avita can offer more comprehensive treatments for wound care. I believe the company has moved past it's lowest point, and I wouldn't be completely shocked if it gets acquired at a potentially frustrating valuation (for longer-term shareholders), similar to how $MNKD acquired $SCPH
0 · Reply
BeefStewart
BeefStewart May. 9 at 6:31 PM
$RCEL wondering if this will go the route of $SCPH @OldManLogan any thoughts here?
1 · Reply
BeefStewart
BeefStewart May. 5 at 4:53 PM
$RCEL I feel really bullish about this, but I understand that the stock price has been languishing over time. One thing I notice is the low trading liquidity. It reminds me of $SCPH last year. Anyone have any insights into earnings expectations?
0 · Reply
BeefStewart
BeefStewart May. 4 at 2:54 PM
$ADMA I remember in March of 2025 when $SCPH received a favorable FDA decision, leading to the stock selling off... It would eventually go up, but selling the news is a real thing sometimes...
1 · Reply